Impact of Obesity on the Utility of Preoperative Prostate-Specific Antigen Velocity to Predict for Relapse After Prostatectomy: A Report from the SEARCH Database

Urology

Volumn 69, Issue 5, 2007, Pages 921-926

  King, Christopher R ^a   Freedland, Stephen J ^b,c   Terris, Martha K ^d,e   Kane, Christopher J ^e,f   Amling, Christopher L ^g,h   Aronson, William J ^i,j   Presti Jr , Joseph C ^a,k  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Hugh Kaul Human Genetics Building   (United States)

^h NAVAL MEDICAL CENTER SAN DIEGO   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^k VA PALO ALTO HEALTH CARE SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BODY MASS; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; TUMOR BIOPSY;

AGE FACTORS; AGED; BIOPSY, NEEDLE; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; COMORBIDITY; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBESITY; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34247601513     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.01.056     Document Type: Article

References (14)

1. D'Amico A.V., Chen M.-H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 121-135
2. Patel D.A., Presti J.C., McNeal J.E., et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol23 (2005) 6157-6162
3. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
4. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
5. Freedland S.J., Aronson W.J., Kane C.J., et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer hospital study group. J Clin Oncol 22 (2004) 446-453
6. Amling C.L., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22 (2004) 439-445
7. Strom S.S., Wang X., Pettaway C.A., et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11 (2005) 6889-6894
8. Bassett W.W., Cooperberg M.R., Sadetsky N., et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 66 (2005) 1060-1065
9. Greene F.L., Page D.L., Flemming I.D., et al. AJCC Manual for Staging Cancer. 6th ed. (2002), Springer Verlag, New York 309-313
10. Veterans Administration Cooperative Urological Research Group, and Gleason D.F. Histological grading and staging of prostatic carcinoma. In: Tannenbaum M. (Ed). Urologic Pathology: The Prostate (1977), Lea & Febiger, Philadelphia 171-187
11. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
12. Dahle S.E., Chokkalinggam A.P., Gao Y.T., et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168 (2002) 599-604
13. Hammarsten J., and Hogstedt B. Hyperinsulinemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39 (2001) 151-158
14. Hammarsten J., and Hogstedt B. Hyperinsulinemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 41 (2005) 1887-1895